Antitumor activities of PSMA×CD3 diabodies by redirected T-cell lysis of prostate cancer cells
01.01.2013
Baum V, Bühler P, Gierschner D, Herchenbach D, Fiala GJ, Schamel WW, Wolf P, Elsässer-Beile U.
Immunotherapy. 2013;5(1):27-38
We engineered a prostate?specific membrane antigen (PSMA)×CD3 diabody and a single?chain diabody for therapeutic purposes. The bacterial expression levels of the diabody were significantly higher as compared to the single?chain diabody, but both constructs retargeted human CD4+ and CD8+ lymphocytes to lyse PSMA?expressing prostate cancer cells in vitro. We could show the formation of conjugates between T cells and target cells upon diabody treatment. In SCID mice bearing PSMA?expressing tumor xenografts, human peripheral blood lymphocytes along with diabody showed an efficient inhibition of tumor growth. We concluded that both diabody formats are promising for further development in anti?tumor therapies.
